An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8+ T Cells

Molecular Therapy Methods and Clinical Development

Volumn 5, Issue , 2017, Pages 142-152

  Palaschak, Brett ^a   Marsic, Damien ^a   Herzog, Roland W ^a   Zolotukhin, Sergei ^a   Markusic, David M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

AAV vector; capsid immunity; hemophilia; mouse model

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; BLOOD CLOTTING FACTOR 9; GAMMA INTERFERON; PREDNISOLONE; THY 1 ANTIGEN; VIRUS CAPSID ANTIGEN;

ADENO ASSOCIATED VIRUS; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HEMOPHILIA B; IMMUNOLOGICAL MEMORY; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE THERAPY; VIRUS CAPSID;

EID: 85020526490     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1016/j.omtm.2017.04.004     Document Type: Article

References (54)

1. 1 Zaiss, A.K., Liu, Q., Bowen, G.P., Wong, N.C., Bartlett, J.S., Muruve, D.A., Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 76 (2002), 4580–4590.
2. 2 Mingozzi, F., Liu, Y.L., Dobrzynski, E., Kaufhold, A., Liu, J.H., Wang, Y., Arruda, V.R., High, K.A., Herzog, R.W., Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest. 111 (2003), 1347–1356.
3. 3 Mount, J.D., Herzog, R.W., Tillson, D.M., Goodman, S.A., Robinson, N., McCleland, M.L., Bellinger, D., Nichols, T.C., Arruda, V.R., Lothrop, C.D. Jr., High, K.A., Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 99 (2002), 2670–2676.
4. 4 Rogers, G.L., Herzog, R.W., Gene therapy for hemophilia. Front. Biosci. (Landmark Ed.) 20 (2015), 556–603.
5. 5 Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12 (2006), 342–347.
6. 6 Mingozzi, F., Maus, M.V., Hui, D.J., Sabatino, D.E., Murphy, S.L., Rasko, J.E., Ragni, M.V., Manno, C.S., Sommer, J., Jiang, H., et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13 (2007), 419–422.
7. 7 Pien, G.C., Basner-Tschakarjan, E., Hui, D.J., Mentlik, A.N., Finn, J.D., Hasbrouck, N.C., Zhou, S., Murphy, S.L., Maus, M.V., Mingozzi, F., et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J. Clin. Invest. 119 (2009), 1688–1695.
8. 8 Finn, J.D., Hui, D., Downey, H.D., Dunn, D., Pien, G.C., Mingozzi, F., Zhou, S., High, K.A., Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol. Ther. 18 (2010), 135–142.
9. 9 Nathwani, A.C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S.N., Bronson, R., Jackson, S., et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol. Ther. 19 (2011), 876–885.
10. 10 Monahan, P., Walsh, C.E., Powell, J.S., Konkle, B.A., Josephson, N.C., Escobar, M., McPhee, S.J., Litchev, B., Cecerle, M., Ewenstein, B.M., et al. Update on a phase 1/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B. J. Thromb. Haemost., 13, 2015, 87.
11. 11 UniQure Biopharma BV, and Chiesi Farmaceutici, SpA. Trial of AAV5-hFIX in severe or moderately severe hemophilia B. National Library of Medicine. 2015, NCT02396342. https://clinicaltrials.gov/show/NCT02396342.
12. 12 Spark Therapeutics, Children's Hospital of Philadelphia, University of Pittsburgh, Royal Prince Alfred Hospital, and St. James's Hospital. Hemophilia B gene therapy - Spark. National Library of Medicine. 2012, NCT01620801. https://clinicaltrials.gov/show/NCT01620801.
13. 13 Spark Therapeutics, Children's Hospital of Philadelphia, The Hemophilia Center of Western Pennsylvania, and Royal Prince Alfred Hospital. LTFU for gene transfer subjects with hemophilia B. National Library of Medicine. 2007, NCT00515710. https://clinicaltrials.gov/show/NCT00515710.
14. 14 Spark Therapeutics and Pfizer. A gene therapy study for hemophilia B. National Library of Medicine. 2015, NCT02484092. https://clinicaltrials.gov/show/NCT02484092.
15. 15 St. Jude Children's Research Hospital, National Heart, Lung, and Blood Institute, Hemophilia of Georgia, Inc., and Children's Hospital of Philadelphia. Dose-escalation study of a self complementary adeno-associated viral vector for gene transfer in hemophilia B. National Library of Medicine. 2009, NCT00979238. https://clinicaltrials.gov/show/NCT00979238.
16. 16 Baxalta US Inc. Open-label single ascending dose of adeno-associated virus serotype 8 factor IX gene therapy in adults with hemophilia B. National Library of Medicine. 2012, NCT01687608. https://clinicaltrials.gov/show/NCT01687608.
17. 17 Herzog, R.W., Immune responses to AAV capsid: are mice not humans after all?. Mol. Ther. 15 (2007), 649–650.
18. 18 Li, H., Lasaro, M.O., Jia, B., Lin, S.W., Haut, L.H., High, K.A., Ertl, H.C., Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates. Mol. Ther. 19 (2011), 2021–2030.
19. 19 Somanathan, S., Breous, E., Bell, P., Wilson, J.M., AAV vectors avoid inflammatory signals necessary to render transduced hepatocyte targets for destructive T cells. Mol. Ther. 18 (2010), 977–982.
20. 20 Siders, W.M., Shields, J., Kaplan, J., Lukason, M., Woodworth, L., Wadsworth, S., Scaria, A., Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice. Hum. Gene Ther. 20 (2009), 11–20.
21. 21 Li, H., Lin, S.W., Giles-Davis, W., Li, Y., Zhou, D., Xiang, Z.Q., High, K.A., Ertl, H.C., A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer. Mol. Ther. 17 (2009), 1215–1224.
22. 22 Wang, L., Figueredo, J., Calcedo, R., Lin, J., Wilson, J.M., Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum. Gene Ther. 18 (2007), 185–194.
23. 23 Li, H., Murphy, S.L., Giles-Davis, W., Edmonson, S., Xiang, Z., Li, Y., Lasaro, M.O., High, K.A., Ertl, H.C., Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol. Ther. 15 (2007), 792–800.
24. 24 Li, C., Hirsch, M., Asokan, A., Zeithaml, B., Ma, H., Kafri, T., Samulski, R.J., Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J. Virol. 81 (2007), 7540–7547.
25. 25 Li, C., Hirsch, M., DiPrimio, N., Asokan, A., Goudy, K., Tisch, R., Samulski, R.J., Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. J. Virol. 83 (2009), 6817–6824.
26. 26 Sabatino, D.E., Mingozzi, F., Hui, D.J., Chen, H., Colosi, P., Ertl, H.C., High, K.A., Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Mol. Ther. 12 (2005), 1023–1033.
27. 27 Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121 (2013), 2224–2233.
28. 28 Zhong, L., Li, B., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R.W., Zolotukhin, I., Warrington, K.H. Jr., Weigel-Van Aken, K.A., et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. USA 105 (2008), 7827–7832.
29. 29 Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18 (2010), 2048–2056.
30. 30 Marsic, D., Govindasamy, L., Currlin, S., Markusic, D.M., Tseng, Y.S., Herzog, R.W., Agbandje-McKenna, M., Zolotukhin, S., Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants. Mol. Ther. 22 (2014), 1900–1909.
31. 31 Nathwani, A.C., Reiss, U.M., Tuddenham, E.G., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371 (2014), 1994–2004.
32. 32 Herzog, R.W., Hemophilia gene therapy: caught between a cure and an immune response. Mol. Ther. 23 (2015), 1411–1412.
33. 33 Harvill, E.T., Osorio, M., Loving, C.L., Lee, G.M., Kelly, V.K., Merkel, T.J., Anamnestic protective immunity to Bacillus anthracis is antibody mediated but independent of complement and Fc receptors. Infect. Immun. 76 (2008), 2177–2182.
34. 34 McNeal, M.M., VanCott, J.L., Choi, A.H., Basu, M., Flint, J.A., Stone, S.C., Clements, J.D., Ward, R.L., CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G). J. Virol. 76 (2002), 560–568.
35. 35 Liao, G., Detre, C., Berger, S.B., Engel, P., de Waal Malefyt, R., Herzog, R.W., Bhan, A.K., Terhorst, C., Glucocorticoid-induced tumor necrosis factor receptor family-related protein regulates CD4(+)T cell-mediated colitis in mice. Gastroenterology 142 (2012), 582–591.e8.
36. 36 Christianson, S.W., Shultz, L.D., Leiter, E.H., Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 42 (1993), 44–55.
37. 37 King, C., Ilic, A., Koelsch, K., Sarvetnick, N., Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117 (2004), 265–277.
38. 38 Kalos, M., June, C.H., Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39 (2013), 49–60.
39. 39 Simpson, S.J., de Jong, Y.P., Comiskey, M., Terhorst, C., Pathways of T cell pathology in models of chronic intestinal inflammation. Int. Rev. Immunol. 19 (2000), 1–37.
40. 40 Ostanin, D.V., Bao, J., Koboziev, I., Gray, L., Robinson-Jackson, S.A., Kosloski-Davidson, M., Price, V.H., Grisham, M.B., T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am. J. Physiol. Gastrointest. Liver Physiol. 296 (2009), G135–G146.
41. 41 Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner-Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24 (2016), 1042–1049.
42. 42 Lisowski, L., Dane, A.P., Chu, K., Zhang, Y., Cunningham, S.C., Wilson, E.M., Nygaard, S., Grompe, M., Alexander, I.E., Kay, M.A., Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506 (2014), 382–386.
43. 43 Grimm, D., Lee, J.S., Wang, L., Desai, T., Akache, B., Storm, T.A., Kay, M.A., In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82 (2008), 5887–5911.
44. 44 Li, W., Asokan, A., Wu, Z., Van Dyke, T., DiPrimio, N., Johnson, J.S., Govindaswamy, L., Agbandje-McKenna, M., Leichtle, S., Eugene Redmond, D. Jr., et al. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol. Ther. 16 (2008), 1252–1260.
45. 45 Maheshri, N., Koerber, J.T., Kaspar, B.K., Schaffer, D.V., Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24 (2006), 198–204.
46. 46 Hui, D.J., Edmonson, S.C., Podsakoff, G.M., Pien, G.C., Ivanciu, L., Camire, R.M., Ertl, H., Mingozzi, F., High, K.A., Basner-Tschakarjan, E., AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes. Mol. Ther. Methods Clin. Dev., 2, 2015, 15029.
47. 47 Strick-Marchand, H., Dusséaux, M., Darche, S., Huntington, N.D., Legrand, N., Masse-Ranson, G., Corcuff, E., Ahodantin, J., Weijer, K., Spits, H., et al. A novel mouse model for stable engraftment of a human immune system and human hepatocytes. PLoS ONE, 10, 2015, e0119820.
48. 48 Rogers, G.L., Zolotukhin, I., Herzog, R.W., Unique role of the TLR9-MyD88 signaling pathway in dendritic cells in AAV capsid-specific CD8+ T cell activation. Mol. Ther., 23, 2015, S208.
49. 49 Kim, Y., Ponomarenko, J., Zhu, Z., Tamang, D., Wang, P., Greenbaum, J., Lundegaard, C., Sette, A., Lund, O., Bourne, P.E., et al. Immune epitope database analysis resource. Nucleic Acids Res. 40 (2012), W525–W530.
50. 50 Nielsen, M., Lundegaard, C., Worning, P., Lauemøller, S.L., Lamberth, K., Buus, S., Brunak, S., Lund, O., Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12 (2003), 1007–1017.
51. 51 Lundegaard, C., Lamberth, K., Harndahl, M., Buus, S., Lund, O., Nielsen, M., NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36 (2008), W509–W512.
52. 52 Peters, B., Sette, A., Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics, 6, 2005, 132.
53. 53 Sidney, J., Assarsson, E., Moore, C., Ngo, S., Pinilla, C., Sette, A., Peters, B., Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res., 4, 2008, 2.
54. 54 Martino, A.T., Herzog, R.W., Anegon, I., Adjali, O., Measuring immune responses to recombinant AAV gene transfer. Methods Mol. Biol. 807 (2011), 259–272.